DefiniGen said it plans to use ERS Genomics' technology to create disease models to support drug discovery for type 2 diabetes and other conditions.
GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.
Axcelead, a Japanese drug discovery service provider, will use the technology to include creation of genetically modified animals in its service offerings.
Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.
The NMI Natural and Medical Sciences Institute at the university and its affiliate will use the patents to expand their cell-based research service offerings.
The deal expands Evotec's existing CRISPR licenses through the Broad Institute and adds to ERS's list of licensees for its gene editing technology.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.
A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.
An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.
In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.